1. Home
  2. TNYA vs KZIA Comparison

TNYA vs KZIA Comparison

Compare TNYA & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenaya Therapeutics Inc.

TNYA

Tenaya Therapeutics Inc.

HOLD

Current Price

$0.80

Market Cap

181.5M

Sector

Health Care

ML Signal

HOLD

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

HOLD

Current Price

$13.11

Market Cap

154.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNYA
KZIA
Founded
2016
1994
Country
United States
Australia
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
181.5M
154.9M
IPO Year
2021
2002

Fundamental Metrics

Financial Performance
Metric
TNYA
KZIA
Price
$0.80
$13.11
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$5.33
$19.50
AVG Volume (30 Days)
2.7M
163.5K
Earning Date
05-07-2026
06-04-2026
Dividend Yield
N/A
N/A
EPS Growth
54.96
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$4.86
52 Week High
$2.35
$17.40

Technical Indicators

Market Signals
Indicator
TNYA
KZIA
Relative Strength Index (RSI) 50.07 47.19
Support Level $0.65 $11.90
Resistance Level $0.80 $14.75
Average True Range (ATR) 0.07 0.99
MACD 0.00 -0.10
Stochastic Oscillator 39.32 32.55

Price Performance

Historical Comparison
TNYA
KZIA

About TNYA Tenaya Therapeutics Inc.

Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Share on Social Networks: